Halma gets warm reviews by City analysts after upgrade

Halma PLC upgraded its full-year organic growth outlook to a low double-digit percentage, driven by strong performance in photonics, which propelled its shares to new all-time highs. Following this, analysts at Citi and UBS raised their consensus revenue and profit estimates by approximately 3-4% for FY26-27, with UBS increasing its share price target to £40 and reiterating a 'Buy' rating. Despite trading at a premium 32x forecast earnings, analysts view this valuation as justified given Halma's low earnings volatility and consistent acquisition track record.

Analysis

Halma PLC has issued a significant upgrade to its full-year outlook, now forecasting low double-digit percentage organic growth, an increase from its prior guidance of a high single-digit rate. This revision is principally driven by exceptional strength in its photonics division, which is experiencing approximately 40% growth. The market has responded positively, with Halma's shares reaching new all-time highs. Analyst sentiment is uniformly bullish; Citi anticipates this guidance will lead to a 3-4% upgrade in 2026 consensus revenue, with adjusted pre-tax profit potentially rising to circa £510 million from £493 million. Reinforcing this outlook, UBS noted a strong book-to-bill ratio exceeding 1.0x, signaling robust order flow and future revenue visibility. Consequently, UBS raised its own revenue and profit estimates by approximately 4% and increased its share price target to £40. While the company's valuation is at a premium, trading at 32 times forecast earnings, analysts at Panmure Liberum consider this justified by Halma's low earnings volatility and a proven acquisition track record, which the current announcement reinforces.

Key Decisions for Investors

• Given the upgraded guidance, strong underlying momentum indicated by a book-to-bill ratio above 1.0x, and positive analyst revisions, investors may view Halma as a compelling case for compounding growth, aligning with the reiterated 'Buy' rating from UBS.
• Investors must weigh the company's premium valuation of 32 times forecast earnings against its qualitative strengths, such as low earnings volatility and a successful acquisition strategy, which analysts believe justify the premium to its peers.
• Monitor the performance of the photonics division and the book-to-bill ratio in subsequent reports, as these are the key metrics underpinning the current bullish thesis and elevated valuation.